GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (FRA:H2K2) » Definitions » E10

XTL Biopharmaceuticals (FRA:H2K2) E10 : €-0.51 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is XTL Biopharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

XTL Biopharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.092. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.51 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of XTL Biopharmaceuticals was 47.70% per year. The lowest was 12.60% per year. And the median was 36.00% per year.

As of today (2024-12-12), XTL Biopharmaceuticals's current stock price is €1.52. XTL Biopharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €-0.51. XTL Biopharmaceuticals's Shiller PE Ratio of today is .


XTL Biopharmaceuticals E10 Historical Data

The historical data trend for XTL Biopharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals E10 Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.67 -0.80 -0.56 -0.52 -

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.46 -0.40 - -0.51

Competitive Comparison of XTL Biopharmaceuticals's E10

For the Biotechnology subindustry, XTL Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Shiller PE Ratio falls into.



XTL Biopharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XTL Biopharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.092/131.7762*131.7762
=0.092

Current CPI (Mar. 2024) = 131.7762.

XTL Biopharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.147 100.560 -0.193
201409 -0.233 100.428 -0.306
201412 -0.243 99.070 -0.323
201503 -0.462 99.621 -0.611
201506 -0.089 100.684 -0.116
201509 -0.178 100.392 -0.234
201512 -0.826 99.792 -1.091
201603 -0.180 100.470 -0.236
201606 -0.178 101.688 -0.231
201609 -0.089 101.861 -0.115
201612 -0.379 101.863 -0.490
201703 -0.280 102.862 -0.359
201706 -0.240 103.349 -0.306
201709 0.336 104.136 0.425
201712 0.000 104.011 0.000
201803 0.324 105.290 0.406
201806 -0.171 106.317 -0.212
201809 0.171 106.507 0.212
201812 0.264 105.998 0.328
201903 0.708 107.251 0.870
201906 -0.531 108.070 -0.647
201909 -0.223 108.329 -0.271
201912 -0.092 108.420 -0.112
202003 0.030 108.902 0.036
202006 -0.178 108.767 -0.216
202009 -0.170 109.815 -0.204
202012 -0.164 109.897 -0.197
202103 0.084 111.754 0.099
202106 -0.166 114.631 -0.191
202109 -0.085 115.734 -0.097
202112 0.233 117.630 0.261
202203 0.084 121.301 0.091
202206 -0.095 125.017 -0.100
202209 -0.142 125.227 -0.149
202212 -0.094 125.222 -0.099
202303 -0.158 127.348 -0.163
202306 -0.062 128.729 -0.063
202309 -0.060 129.860 -0.061
202312 0.000 129.419 0.000
202403 0.092 131.776 0.092

Add all the adjusted EPS together and divide 10 will get our e10.


XTL Biopharmaceuticals  (FRA:H2K2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


XTL Biopharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

XTL Biopharmaceuticals Headlines

No Headlines